In May 2024, Imugene's CEO & Managing Director Leslie Chong delivered a dynamic 'stand-up and pitch' presentation at the JMM & Ethica Capital Innovation and Investment Insights in Sydney.
Of all the presentations I have seen of Leslie this is one of her best.
Leslie is relaxed, confident and in command as she presents the investment potential of Azer-cel, Vaxinia and OnCarlytics.
The video is just of Leslie delivering the presentation without the slides she is talking to.
As a reference I have also included a link to the July 2024 Investor Presentation
https://static1.squarespace.com/static/5b63d41b3e2d09b1f56bf483/t/66863692314049367616057b/1720071833068/Investor Presentation July 2024.pdf
Azer-cel is an investigational anti-CD19 allogeneic chimeric antigen receptor (CAR) T cell therapy.
It’s designed to treat patients with relapsed or refractory non-Hodgkin lymphoma (NHL) who have relapsed following treatment with an autologous CAR T.
View attachment 6317823
Azer-cel is currently in a Phase 1b confirmation study with preliminary results due to be released later this year to be followed by discussions with the FDA in 2025 for a registrational trial.
Leslie explains how CAR-T therapies in the treatment of blood cancers account for 10% of the cancer market and the potential for the CF33-CD19 Oncolytic virus also known as onCARlytics to address the remaining 90% of the market comprising solid tumors.
The ability of onCARlytics to seek out solid tumor cells, infiltrate them and force them to express the CD19 protein on their surface and so prime them for destruction by a CD19 targeting CAR-T therapy presents a paradigm shift in the treatment of solid tumors.
At 12.17 "now you can cover a solid tumor with cd19 add a CAR-T that's directed for CD19 and then in that process you create a very smart bomb that goes after your target then obliterates it and gets your immune system to the fight ... this is one of those products that is world class, there is nothing like it in the world. When I speak with US investors this is what excites them, this is how we are going to revolutionize solid tumor cancer treatment"
Leslie also confirmed that in a pre-clinical study with Azer-cel and onCARlytics "within 72 hours we saw a complete killing in TNBC as well as gastric ... I have run over 200 or so phase 1 studies and I have never seen anything like it"
Imugene is seeking an FDA IND approval for a combination trial in 2025 with onCARlytics and Azer-cel.
OnCARlytics is currently in a phase 1 study and in combination with Amgen's Blincyto with data due in early 2025.
In a review of an April 2024 publication in the Journal of the American College Surgeons of a pre-clinical trial as previously posted by
@melburnian
Using Oncolytic Virus to Retask CD19-Chimeric Antigen Receptor T Cells for Treatment of Pancreatic Cancer: Toward a Universal Chimeric Antigen Receptor T-Cell Strategy for Solid Tumor
https://journals.lww.com/journalacs...colytic_virus_to_retask_cd19_chimeric.14.aspx
A question was raised as to the disparity of CD19 expression on the cell surface, - 100% in vitro versus only 20% in vivo. In response Dr Chen replied -
"Part of the reason for the disparity ... is a dose issue ... the dosage we used in our study was not the maximum the mice could tolerate. The reason we did not use a higher dose was that our CF33-CD19t virus is so efficacious in antitumor activity that if we gave a higher dose, our virus would likely eradicate the tumor before we could show the synergistic effect of the CD19-CAR T cells.
GLTAH - Go Team Imugene
.
(20min delay)